FindTrial
Sign In

AZD0780 Placebo

DRUG4 trials

Sponsors

Astrazeneca AB, AstraZeneca AB

Conditions

Atherosclerotic Cardiovascular DiseaseAtherosclerotic cardiovascular diseaseDyslipidemia Dyslipidemias are alterations to the plasma lipid profile associated often with clinical condition. A common form of dyslipidemia is Hypercholesterolemia due to high level of LDL-cholesterolHeterozygous familial hypercholesterolaemiaHyperlipidemiasuch as Ischemic Heart Disease and Ischemic Stroke. CVD is a leading cause of global mortality and a contributor to disability.which is a major risk factor for Cardiovascular Disease (CVD)

Phase 2

A Phase IIb, Multicenter, Randomized, Parallel-group, Double- blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AZD0780 in Participants with Dyslipidemia
CompletedCTIS2023-506197-12-00
Astrazeneca ABDyslipidemia Dyslipidemias are alterations to the plasma lipid profile associated often with clinical condition. A common form of dyslipidemia is Hypercholesterolemia due to high level of LDL-cholesterol, such as Ischemic Heart Disease and Ischemic Stroke. CVD is a leading cause of global mortality and a contributor to disability., which is a major risk factor for Cardiovascular Disease (CVD)
Start: 2024-02-07End: 2024-09-25Target: 209Updated: 2024-04-12

Phase 3

A Phase III, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Effect of AZD0780 on Low Density Lipoprotein Cholesterol in Patients With Heterozygous Familial Hypercholesterolaemia
Active, not recruitingCTIS2025-520520-17-00
AstraZeneca ABHeterozygous familial hypercholesterolaemia
Start: 2025-09-05Target: 152Updated: 2025-12-12
A Phase III, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Effect of AZD0780 on Low-Density Lipoprotein Cholesterol in Patients With Elevated Low-Density Lipoprotein Cholesterol and Clinical Atherosclerotic Cardiovascular Disease or at Risk for a First Atherosclerotic Cardiovascular Disease Event
Active, not recruitingCTIS2025-520521-21-00
AstraZeneca ABAtherosclerotic cardiovascular disease, Hyperlipidemia
Start: 2025-09-02Target: 780Updated: 2026-01-15
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event
RecruitingCTIS2025-520519-14-00
AstraZeneca ABAtherosclerotic Cardiovascular Disease
Start: 2025-09-03Target: 3531Updated: 2026-01-19